Elicio Therapeutics(ELTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ELTX Elicio Therapeutics

Pre-Mkt 07-10 08:14:27 EDT

3.49

+0.00

0.00%

盘前3.49

+0.000.00%

08:10 EDT

High3.59	Low3.32	Vol1.05M
Open3.48	D1 Closing3.49	Amplitude7.74%
Mkt Cap80.34M	Tradable Cap71.84M	Total Shares23.02M
T/O3.62M	T/O Rate5.09%	Tradable Shares20.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ELTX","market":"US","secType":"STK","nameCN":"Elicio Therapeutics","latestPrice":3.49,"timestamp":1783627200000,"preClose":3.49,"halted":0,"volume":1047947,"hourTrading":{"tag":"盘前","latestPrice":3.49,"preClose":3.49,"latestTime":"08:10 EDT","volume":1093,"amount":3777.6968799,"timestamp":1783685417065,"change":0,"changeRate":0,"amplitude":0.04298},"delay":0,"changeRate":0,"floatShares":20583700,"shares":23020200,"eps":-2.4167,"marketStatus":"Pre-Mkt","change":0,"latestTime":"07-10 08:14:27 EDT","open":3.48,"high":3.59,"low":3.32,"amount":3619650.646291,"amplitude":0.077364,"askPrice":3.49,"askSize":200,"bidPrice":3.45,"bidSize":242,"shortable":3,"etf":0,"ttmEps":-2.4167,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1783690200000},"marketStatusCode":1,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":3.49,"preHourTrading":{"tag":"盘前","latestPrice":3.49,"preClose":3.49,"latestTime":"08:10 EDT","volume":1093,"amount":3777.6968799,"timestamp":1783685417065,"change":0,"changeRate":0,"amplitude":0.04298},"postHourTrading":{"tag":"盘后","latestPrice":3.49,"preClose":3.49,"latestTime":"19:59 EDT","volume":11095,"amount":38624.7093,"timestamp":1783641578658,"change":0,"changeRate":0,"amplitude":0.054355},"volumeRatio":0.38255053500474345,"impliedVol":1.797,"impliedVolPercentile":0.66},"requestUrl":"/m/hq/s/ELTX","defaultTab":"news","newsList":[{"id":"2649067460","title":"Elicio Therapeutics Closes $15 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2649067460","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649067460?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:39","pubTimestamp":1783373991,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics  said late Monday it has closed its registered direct offering under a definitive securities purchase agreement, led by two new fundamental institutional investors and a large existing shareholder, to purchase an aggregate of 4.4 million common shares for gross proceeds of approximately $15 million.Elicio said it intends to use the net proceeds from the offering, along with existing cash, cash equivalents and marketable securities, to fund the planned phase 1 clinical development of ELI-002 7P in metastatic pancreatic ductal adenocarcinoma, and its pipeline and platform, as well as for working capital and general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ELTX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649679945","title":"Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649679945?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:05","pubTimestamp":1783368300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUA9ZQ2LM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648682171","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2648682171","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648682171?lang=en_us&edition=fundamental","pubTime":"2026-07-03 01:58","pubTimestamp":1783015092,"startTime":"0","endTime":"0","summary":"Idaho Copper  priced its underwritten public offering of stocks and warrants at $4.85 apiece, targeting about $18 million in gross proceeds, it said late Wednesday.The shares began trading on Thursday, down 34% amid intraday trading volume of about 415,000.Elicio Therapeutics'  shares sank 34% after the company said Thursday it priced a registered direct offering of about 4.4 million shares.More than 3.43 million shares of the company traded intraday compared with a daily average of about 1.45 million.Ouster  priced an underwritten public offering of 3.62 million common shares at $55.22 apiece, for expected gross proceeds of about $200 million, the company said Thursday.Shares slumped 18%, with intraday trading volume at about 6.65 million versus a daily average of roughly 4.41 million.Price: 4.10, Change: -2.15, Percent Change: -34.40","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ELTX","OUST","COPR","BK4157","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648068125","title":"U.S. Stocks on the Move-silicom, Blue Owl, Intel","url":"https://stock-news.laohu8.com/highlight/detail?id=2648068125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648068125?lang=en_us&edition=fundamental","pubTime":"2026-07-03 00:19","pubTimestamp":1783009173,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Silicom, Blue Owl, IntelWorkspace search string for individual stock moves:STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nL6N4341RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","SNDG","ONTO","YRD","UHS","SILC","SNDC","ELTX","INTW","LHAI","CVEO","KLAC","MEI","RVNL","HONA","LCDL","NWMX","OUST","ARCT","SNDQ","NEXA","MRNY","OWL","FPS","TER","SNXX","HSBA.UK","NEM","CWD","INTC","SNDK","FC","CLRO","RIVN","LCIZ","GE","MRNX","SNDU","LCID","LINT","WBX","TERG","TMO","AU","JPMO","HCA","KLAG","DLTR","JPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648168897","title":"Wall Street Set to Open Higher in Thursday Trading; US Adds Only 57,000 Jobs in June","url":"https://stock-news.laohu8.com/highlight/detail?id=2648168897","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648168897?lang=en_us&edition=fundamental","pubTime":"2026-07-02 21:23","pubTimestamp":1782998598,"startTime":"0","endTime":"0","summary":"US stocks look set to open higher in Thursday's trading session as investors parse key employment data released earlier in the morning.Dow Jones Industrial Average futures were up 0.3%, S&P 500 future","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACWI","QID","SPY","TSPY","DVY",".SPX","ONEQ","USDE","SH","JEPI","IVV","DDM","JEPQ","SDS",".IXIC","QLD","DJIA","NQmain","HIBS","BMAY","VOOG","XLI","LHAI","RSP","VTI","GSLC","TENX","SPUS","SPXU","MYMmain","SURG","TOPT","VTV","SPXS","ETFT","YMAX","VBK","ELTX","INLF","IYW","QQQM","QQQY","XYLD","SQQQ","QDTE","XLG","PSQ",".DJI","SPHQ","RSPU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648504129","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2648504129","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648504129?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:32","pubTimestamp":1782991951,"startTime":"0","endTime":"0","summary":"Linkhome  shares were down 31% in Thursday premarket activity, following the previous session's 315% gain after the company announced the acquisition of Mortgage One Group.Eason Technology  stock was down 23%, following the previous session's 141% gain.INLIF  shares were down 23% after its board approved a 1-for-200 share combination of the company's shares.Elicio Therapeutics  stock was down 21% after pricing a registered direct offering of about 4.4 million shares.Franklin Covey  shares were down 18% after the company lowered its fiscal 2026 revenue guidance.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4164","BK4139","DXF","BK4161","ELTX","LHAI","INLF","BK4123","FC","BK4079","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648505782","title":"Elicio Therapeutics announces pricing of $15M registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2648505782","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648505782?lang=en_us&edition=fundamental","pubTime":"2026-07-02 17:30","pubTimestamp":1782984613,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (ELTX) announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-announces-pricing-of-15m-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-announces-pricing-of-15m-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ELTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648577672","title":"Elicio Therapeutics Prices $15 Million Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2648577672","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648577672?lang=en_us&edition=fundamental","pubTime":"2026-07-02 15:39","pubTimestamp":1782977961,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics  has priced a registered direct offering of about 4.4 million common shares for gross proceeds of about $15 million, the company said Thursday.The offering, led by two new fundamental institutional investors and an existing shareholder, is expected to close on or about July 6, Elicio said.Net proceeds will be used to primarily fund the planned phase 1 clinical development of ELI-002 7P, as well as its pipeline and platform, working capital, and general corporate purposes, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ELTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648576088","title":"Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2648576088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648576088?lang=en_us&edition=fundamental","pubTime":"2026-07-02 12:25","pubTimestamp":1782966309,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nTUA4HSKMX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647792373","title":"Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2647792373","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647792373?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:00","pubTimestamp":1782734400,"startTime":"0","endTime":"0","summary":"BOSTON, June  29, 2026  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/29/3318881/0/en/Elicio-Therapeutics-Added-to-Russell-2000-and-Russell-3000-Indexes.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ELTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646706278","title":"Elicio Therapeutics Posts Amplify-7p Presentation on Eli-002 7P in Metastatic Mkras Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2646706278","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646706278?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:06","pubTimestamp":1782389188,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics posts AMPLIFY-7P presentation on ELI-002 7P in metastatic mKRAS pancreatic cancerElicio Therapeutics published an AMPLIFY-7P research presentation outlining a development path for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL3L6Fz4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ELTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646846919","title":"Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646846919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646846919?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:40","pubTimestamp":1782333620,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX). Ph...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-phathom-pharmaceuticals-phat-and-elicio-therapeutics-eltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-phathom-pharmaceuticals-phat-and-elicio-therapeutics-eltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4139","BK4137","LU0128526141.USD","PHAT","BK4588","XBI","ELTX","BK4581","BK4007","XLV","LABU","BK4585","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645026491","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Damora Therapeutics (DMRA), Summit Therapeutics (SMMT) and Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645026491","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645026491?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:33","pubTimestamp":1782124427,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Damora Therapeutics (DMRA), Summit Therapeutics (S...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-damora-therapeutics-dmra-summit-therapeutics-smmt-and-elicio-therapeutics-eltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-damora-therapeutics-dmra-summit-therapeutics-smmt-and-elicio-therapeutics-eltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELTX","BK4137","XLV","LABU","LU2488822045.USD","XBI","BK4007","HCSG","LU0029874061.USD","BK4585","BK4588","SMMT","DMRA","LU0128526141.USD","BK4139","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644033710","title":"Elicio Therapeutics Coverage Assumed by Ladenburg Thalmann at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2644033710","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644033710?lang=en_us&edition=fundamental","pubTime":"2026-06-19 03:13","pubTimestamp":1781809980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ELTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 18, 2026 15:13 ET (19:13 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ELTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644086716","title":"Elicio Therapeutics assumed with a Buy at Ladenburg","url":"https://stock-news.laohu8.com/highlight/detail?id=2644086716","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644086716?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:15","pubTimestamp":1781788522,"startTime":"0","endTime":"0","summary":"Ladenburg assumed coverage of Elicio Therapeutics (ELTX) with a Buy rating and $12 price target The firm views the selloff post the Phase II ELI-00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-assumed-with-a-buy-at-ladenburg-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-assumed-with-a-buy-at-ladenburg-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELTX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644669088","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2644669088","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644669088?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:34","pubTimestamp":1781782477,"startTime":"0","endTime":"0","summary":"INLIF  shares were down 43% in Thursday premarket activity, extending the previous session's 88% decline.Sleep Number  stock was down 40% after the company said in a regulatory filing that it received a Nasdaq delisting notice related to its Chapter 11 filing and associated public interest and compliance concerns.NovoCure  shares were down 21% after a phase 3 trial evaluating its Tumor Treating Fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.Elicio Therapeutics  stock was down 20%, following Wednesday's 70% gain.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","BK4139","ELTX","BK4585","BK4161","BK4588","SNBRQ","NVCR","SNBR","INLF","BK4534","BK4548","BK4178","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644374414","title":"Elicio Reports Complete Responses in 3 Pancreatic Cancer Patients After ELI-002 7P, Nivolumab Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2644374414","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644374414?lang=en_us&edition=fundamental","pubTime":"2026-06-17 22:20","pubTimestamp":1781706041,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics  said Wednesday that three patients who received ELI-002 7P in the phase 2 Amplify-7P study and later experienced disease progression subsequently achieved complete radiographic and complete metabolic responses after receiving nivolumab-based therapy.The company said it intends to continue monitoring additional patients who participated in the Amplify-7P study and are currently following a similar course of treatment.Elicio said the findings support further evaluation of checkpoint inhibitor combinations and could help inform future development strategies in metastatic pancreatic ductal adenocarcinoma and the design of a planned phase 3 trial in adjuvant PDAC.Subject to funding, the company also plans to initiate a phase 1 study evaluating ELI-002 7P in combination with gemcitabine/nab-paclitaxel chemotherapy and an anti-PD-1 inhibitor in treatment-naive metastatic mKRAS pancreatic cancer.Price: 3.16, Change: +0.40, Percent Change: +14.49","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","ELTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644419887","title":"Elicio Therapeutics reports complete responses in pancreatic cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644419887","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644419887?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:28","pubTimestamp":1781702934,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (ELTX) reported preliminary clinical observations from its recently completed Phase 2 AMPLIFY-7P study of its cancer immunother...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-reports-complete-responses-in-pancreatic-cancer-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-reports-complete-responses-in-pancreatic-cancer-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","ELTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745670","title":"Elicio Therapeutics plans Phase 1 trial of ELI-002 7P plus anti-PD-1, chemo in metastatic mKRAS pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745670","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745670?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:03","pubTimestamp":1781697789,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics reported preliminary Phase 2 AMPLIFY-7P observations that support testing ELI-002 7P with checkpoint inhibitors in metastatic mKRAS pancreatic cancer.Results have not been presented yet; a virtual key opinion leader event is scheduled for June 24, 2026.Three patients later achieved confirmed complete tumor responses on nivolumab-based therapy, suggesting ELI-002 7P may prime sensitivity to immunotherapy.The company plans a funding-dependent Phase 1 trial in first-line metastatic mKRAS PDAC combining ELI-002 7P, standard chemotherapy, and an anti-PD-1 drug.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLgS6Pq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","NDAQ","BK4112","ELTX","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","BK4585","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4139","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","BK4007","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745653","title":"Elicio Therapeutics - Complete Responses Observed in Mss/Mmr-P Patients With Historically Checkpoint Inhibitor Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745653?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:00","pubTimestamp":1781697605,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA3JN5DY:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELTX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.elicio.com","stockEarnings":[{"period":"1week","weight":0.0839},{"period":"1month","weight":-0.7542},{"period":"3month","weight":-0.6562},{"period":"6month","weight":-0.567},{"period":"1year","weight":-0.579},{"period":"ytd","weight":-0.5616}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0199},{"period":"3month","weight":0.1063},{"period":"6month","weight":0.083},{"period":"1year","weight":0.2045},{"period":"ytd","weight":0.1023}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.025227},{"month":2,"riseRate":0.2,"avgChangeRate":0.020436},{"month":3,"riseRate":0.5,"avgChangeRate":0.087379},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.052623},{"month":5,"riseRate":0.833333,"avgChangeRate":0.199324},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.268302},{"month":7,"riseRate":0.5,"avgChangeRate":0.032119},{"month":8,"riseRate":0.4,"avgChangeRate":-0.06958},{"month":9,"riseRate":0.6,"avgChangeRate":0.034992},{"month":10,"riseRate":0.2,"avgChangeRate":-0.198973},{"month":11,"riseRate":0.4,"avgChangeRate":-0.034248},{"month":12,"riseRate":0.4,"avgChangeRate":-0.005753}],"exchange":"NASDAQ","name":"Elicio Therapeutics","nameEN":"Elicio Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Elicio Therapeutics(ELTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Elicio Therapeutics(ELTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Elicio Therapeutics,ELTX,Elicio Therapeutics股票,Elicio Therapeutics股票老虎,Elicio Therapeutics股票老虎国际,Elicio Therapeutics行情,Elicio Therapeutics股票行情,Elicio Therapeutics股价,Elicio Therapeutics股市,Elicio Therapeutics股票价格,Elicio Therapeutics股票交易,Elicio Therapeutics股票购买,Elicio Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Elicio Therapeutics(ELTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Elicio Therapeutics(ELTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction